8-K Announcements
6Material company update
Dec 30, 2025·SEC
Material company update
Dec 12, 2025·SEC
Material company update
Dec 9, 2025·SEC
Merus N.V.(MRUS)Earnings, Financials & Key Ratios
MRUS•NASDAQ
Price updated May 1, 2026
AboutMerus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Show more
- Revenue$35M-12.4%
- EBITDA-$260M-86.6%
- Net Income-$208M-48.1%
- EPS (Diluted)-3.35-11.7%
- Gross Margin37.15%-49.5%
- EBITDA Margin-746.12%-112.9%
- Operating Margin-752.96%-111.4%
- Net Margin-595.93%-69.0%
- ROE-41.39%+11.0%
MRUS Key Insights
Merus N.V. (MRUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 24.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MRUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRUS Price & Volume
Merus N.V. (MRUS) stock price & volume — 10-year historical chart
Loading chart...
MRUS Growth Metrics
Merus N.V. (MRUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.92%
5 Years4.68%
3 Years-6.84%
TTM55.9%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-36.92%
Return on Capital
10 Years-47.36%
5 Years-38.34%
3 Years-44.57%
Last Year-48.43%
MRUS Recent Earnings
Merus N.V. (MRUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q4 2025Latest
Oct 31, 2025Metric
Actual
Est
EPS
$1.23+0.0%
$1.23
Rev
$10M+15.8%
$9M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$2.23-90.6%
$1.17
Rev
$9M-10.1%
$10M
Q2 2025
May 7, 2025Metric
Actual
Est
EPS
$1.40-20.7%
$1.16
Rev
$29M+289.8%
$7M
Q1 2025
Feb 27, 2025Metric
Actual
Est
EPS
$0.41+53.9%
$0.89
Rev
$9M-10.5%
$11M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Oct 31, 2025 | $1.23vs $1.23+0.0% | $10Mvs $9M+15.8% |
| Q3 2025 | Aug 5, 2025 | $2.23vs $1.17-90.6% | $9Mvs $10M-10.1% |
| Q2 2025 | May 7, 2025 | $1.40vs $1.16-20.7% | $29Mvs $7M+289.8% |
| Q1 2025 | Feb 27, 2025 | $0.41vs $0.89+53.9% | $9Mvs $11M-10.5% |
Based on last 12 quarters of dataView full earnings history →
MRUS Peer Comparison
Merus N.V. (MRUS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZYME | 1.7B | 23.14 | -21.43 | 38.87% | -126.33% | -0.25% | 0.07 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 |
Compare MRUS vs Peers
Merus N.V. (MRUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRUS Income Statement
Merus N.V. (MRUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.51M | 21.91M | 33.5M | 27.76M | 24.51M | 43.15M | 38.84M | 39.81M | 34.88M | 51.17M |
Revenue Growth % | 31.76% | 773.11% | 52.86% | -17.15% | -11.69% | 76.02% | -9.99% | 2.5% | -12.38% | 55.9% |
Cost of Goods Sold | 18.42M | 34.13M | 47.81M | 49.64M | 57.33M | 86.27M | 9.95M | 10.5M | 21.92M | 162.48M |
COGS % of Revenue | 734.02% | 155.72% | 142.7% | 178.85% | 233.91% | 199.94% | 25.63% | 26.38% | 62.85% | - |
Gross Profit | -15.91M▲ 0% | -12.21M▲ 23.3% | -14.31M▼ 17.2% | -21.88M▼ 53.0% | -32.82M▼ 50.0% | -43.12M▼ 31.4% | 28.88M▲ 167.0% | 29.31M▲ 1.5% | 12.96M▼ 55.8% | -111.3M▲ 0% |
Gross Margin % | -634.02% | -55.72% | -42.7% | -78.85% | -133.91% | -99.94% | 74.37% | 73.62% | 37.15% | -217.5% |
Gross Profit Growth % | -11.47% | 23.28% | -17.17% | -52.97% | -49.99% | -31.37% | 166.98% | 1.46% | -55.78% | - |
Operating Expenses | 11.97M | 23.09M | 25.62M | 30.41M | 29.29M | 35.93M | 178.34M | 171.11M | 275.58M | 220.34M |
OpEx % of Revenue | 476.77% | 105.37% | 76.49% | 109.56% | 119.5% | 83.28% | 459.21% | 429.84% | 790.11% | - |
Selling, General & Admin | 4.83M | 14.32M | 25.62M | 28.8M | 29.29M | 35.93M | 48.75M | 54.2M | 79.96M | 88.31M |
SG&A % of Revenue | 192.23% | 65.37% | 76.49% | 103.78% | 119.5% | 83.28% | 125.52% | 136.15% | 229.24% | - |
Research & Development | 18.42M | 34.13M | 52.17M | 53.65M | 62.25M | 94.44M | 148.23M | 132.75M | 229.9M | 306.31M |
R&D % of Revenue | 734.02% | 155.72% | 155.73% | 193.3% | 253.95% | 218.88% | 381.68% | 333.49% | 659.14% | - |
Other Operating Expenses | -11.28M | -25.36M | -52.17M | -52.05M | -62.25M | -94.44M | -18.64M | -15.85M | -34.28M | -3M |
Operating Income | -27.88M▲ 0% | -35.3M▼ 26.6% | -39.93M▼ 13.1% | -52.29M▼ 31.0% | -62.11M▼ 18.8% | -79.05M▼ 27.3% | -149.46M▼ 89.1% | -141.8M▲ 5.1% | -262.63M▼ 85.2% | -331.64M▲ 0% |
Operating Margin % | -1110.8% | -161.09% | -119.19% | -188.41% | -253.41% | -183.22% | -384.84% | -356.22% | -752.96% | -648.06% |
Operating Income Growth % | -20.64% | -26.62% | -13.11% | -30.96% | -18.78% | -27.27% | -89.06% | 5.12% | -85.21% | - |
EBITDA | -27.65M | -34.98M | -39.27M | -51.28M | -60.93M | -77.75M | -148.26M | -139.5M | -260.24M | -329.45M |
EBITDA Margin % | -1101.47% | -159.63% | -117.23% | -184.75% | -248.59% | -180.2% | -381.75% | -350.44% | -746.12% | -643.78% |
EBITDA Growth % | -20.63% | -26.54% | -12.25% | -30.58% | -18.83% | -27.6% | -90.69% | 5.91% | -86.55% | -57.54% |
D&A (Non-Cash Add-back) | 234K | 318K | 658.17K | 1.01M | 1.18M | 1.3M | 1.2M | 2.3M | 2.39M | 2.19M |
EBIT | -26.39M | -34.26M | -39.93M | -50.69M | -62.11M | -79.05M | -149.46M | -141.8M | -262.63M | -325.86M |
Net Interest Income | 92.55K | 1.11M | 2.13M | 1.89M | 300K | -129K | 2.72M | 14.51M | 30.79M | 30.35M |
Interest Income | 92.55K | 1.33M | 2.13M | 1.89M | 300K | 0 | 2.72M | 14.51M | 30.79M | 30.35M |
Interest Expense | 0 | 227.94K | 0 | 0 | 0 | 129K | 0 | 0 | 0 | 0 |
Other Income/Expense | -19.56M | -29.22M | 15.4M | 3.3M | -7.48M | 20.56M | 27.83M | 4.35M | 62.64M | 6.71M |
Pretax Income | -47.44M▲ 0% | -64.53M▼ 36.0% | -24.53M▲ 62.0% | -48.99M▼ 99.7% | -69.59M▼ 42.0% | -58.49M▲ 15.9% | -121.63M▼ 107.9% | -137.45M▼ 13.0% | -199.99M▼ 45.5% | -324.94M▲ 0% |
Pretax Margin % | -1889.92% | -294.43% | -73.23% | -176.52% | -283.91% | -135.58% | -313.17% | -345.3% | -573.37% | -634.96% |
Income Tax | 0 | 249K | 178.94K | 172.95K | 411.75K | 209.99K | 895.61K | 2.89M | 7.87M | 9.97M |
Effective Tax Rate % | 0% | -0.39% | -0.73% | -0.35% | -0.59% | -0.36% | -0.74% | -2.1% | -3.93% | -3.07% |
Net Income | -47.44M▲ 0% | -64.77M▼ 36.5% | -24.71M▲ 61.8% | -49.17M▼ 99.0% | -70M▼ 42.4% | -58.7M▲ 16.1% | -122.52M▼ 108.7% | -140.34M▼ 14.5% | -207.85M▼ 48.1% | -334.9M▲ 0% |
Net Margin % | -1889.92% | -295.57% | -73.77% | -177.15% | -285.59% | -136.06% | -315.48% | -352.56% | -595.93% | -654.43% |
Net Income Growth % | -103.98% | -36.55% | 61.85% | -98.96% | -42.37% | 16.14% | -108.71% | -14.55% | -48.1% | -50.28% |
Net Income (Continuing) | -47.44M | -64.77M | -24.71M | -49.17M | -70M | -58.7M | -122.52M | -140.34M | -207.85M | -334.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.75▲ 0% | -3.81▼ 1.6% | -1.28▲ 66.4% | -2.28▼ 78.1% | -2.92▼ 28.1% | -1.73▲ 40.8% | -2.92▼ 68.8% | -3.00▼ 2.7% | -3.35▼ 11.7% | -4.43▲ 0% |
EPS Growth % | -127.27% | -1.6% | 66.4% | -78.13% | -28.07% | 40.75% | -68.79% | -2.74% | -11.67% | -36.92% |
EPS (Basic) | -3.75 | -3.81 | -1.28 | -2.28 | -2.92 | -1.73 | -2.92 | -3.00 | -3.35 | - |
Diluted Shares Outstanding | 13.23M | 19.2M | 22.29M | 24.22M | 29.26M | 38.64M | 44.92M | 51.61M | 64.22M | 75.68M |
Basic Shares Outstanding | 13.23M | 19.2M | 22.29M | 24.22M | 29.26M | 38.64M | 44.92M | 51.61M | 64.22M | 75.68M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MRUS Balance Sheet
Merus N.V. (MRUS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 74.8M | 225.7M | 223.79M | 247.37M | 217.99M | 424.18M | 306.44M | 368.81M | 569.07M | 590.76M |
Cash & Short-Term Investments | 59.86M | 220.41M | 215.74M | 239.76M | 207.75M | 410.43M | 290.23M | 355.18M | 537.03M | 542.95M |
Cash Only | 59.86M | 179.57M | 164.43M | 197.61M | 163.08M | 241.44M | 147.75M | 205.05M | 293.29M | 313.76M |
Short-Term Investments | 0 | 40.84M | 51.31M | 42.15M | 44.67M | 168.99M | 142.48M | 150.13M | 243.73M | 229.19M |
Accounts Receivable | 1.23M | 3.78M | 4.86M | 2.65M | 1.75M | 6.67M | 4.7M | 3.98M | 4.71M | 19.41M |
Days Sales Outstanding | 179.39 | 62.9 | 52.92 | 34.88 | 26.04 | 56.45 | 44.15 | 36.5 | 49.29 | 110.77 |
Inventory | 12.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 246.84 | - | - | - | - | - | - | - | - | - |
Other Current Assets | 113.58K | 0 | 1.08M | 1.38M | 1.06M | 2.17M | 2.2M | 727K | 1.72M | 5.51M |
Total Non-Current Assets | 1.25M | 10.4M | 26.18M | 16.01M | 13.22M | 32.42M | 70.1M | 86.68M | 213.62M | 181.23M |
Property, Plant & Equipment | 681.5K | 1.4M | 2.77M | 8.93M | 8.02M | 7.28M | 24.84M | 23.5M | 20.02M | 19.63M |
Fixed Asset Turnover | 3.68x | 15.64x | 12.10x | 3.11x | 3.06x | 5.92x | 1.56x | 1.69x | 1.74x | 2.51x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 393.34K | 374.31K | 2.8M | 2.88M | 2.84M | 2.35M | 1.95M | 1.8M | 1.68M | 1.49M |
Long-Term Investments | 0 | 8.47M | 19.38M | 2.01M | 0 | 20.3M | 36.46M | 57.31M | 187.01M | 710.67M |
Other Non-Current Assets | 175.63K | 154.76K | 1.23M | 1.91M | 1.95M | 2.08M | 4.81M | 2.87M | 953K | 2.92M |
Total Assets | 76.05M▲ 0% | 236.11M▲ 210.5% | 249.96M▲ 5.9% | 263.38M▲ 5.4% | 231.22M▼ 12.2% | 456.6M▲ 97.5% | 376.54M▼ 17.5% | 455.49M▲ 21.0% | 785.13M▲ 72.4% | 771.99M▲ 0% |
Asset Turnover | 0.03x | 0.09x | 0.13x | 0.11x | 0.11x | 0.09x | 0.10x | 0.09x | 0.04x | 0.06x |
Asset Growth % | 95.97% | 210.47% | 5.87% | 5.37% | -12.21% | 97.48% | -17.53% | 20.97% | 72.37% | 119.24% |
Total Current Liabilities | 8.15M | 22.46M | 33.14M | 36.79M | 46.75M | 71.9M | 78.93M | 69.09M | 87.08M | 74.11M |
Accounts Payable | 2.3M | 3.43M | 3.24M | 3.03M | 3.13M | 13.24M | 9.83M | 4.6M | 4.16M | 7.17M |
Days Payables Outstanding | 45.53 | 36.64 | 24.73 | 22.27 | 19.9 | 56.01 | 360.62 | 159.96 | 69.33 | 23.24 |
Short-Term Debt | 175.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7M | 2.36M |
Deferred Revenue (Current) | 1.93M | 8.66M | 19.37M | 18.84M | 20.18M | 34.66M | 29.42M | 22.68M | 29.93M | 104.68M |
Other Current Liabilities | 231.38K | 535.07K | 207.45K | 21K | 11K | 1.11M | 38K | 35K | 103K | 30.97M |
Current Ratio | 9.17x | 10.05x | 6.75x | 6.72x | 4.66x | 5.90x | 3.88x | 5.34x | 6.54x | 7.97x |
Quick Ratio | 7.64x | 10.05x | 6.75x | 6.72x | 4.66x | 5.90x | 3.88x | 5.34x | 6.54x | 7.97x |
Cash Conversion Cycle | 380.71 | - | - | - | - | - | - | - | - | 87.53 |
Total Non-Current Liabilities | 32.1M | 156.2M | 111.73M | 95.29M | 82.21M | 68.5M | 50.56M | 30.06M | 47.69M | 36.26M |
Long-Term Debt | 335.49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 3.87M | 2.52M | 2.26M | 11.79M | 10.49M | 8.21M | 33.2M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.11M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | -1.11M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40.26M | 178.65M | 144.87M | 132.08M | 128.95M | 140.4M | 129.49M | 99.15M | 134.77M | 110.36M |
Total Debt | 511.13K | 0 | 0 | 5.25M | 3.95M | 3.75M | 13.47M | 12.16M | 9.91M | 10.52M |
Net Debt | -59.35M | -179.57M | -164.43M | -192.36M | -159.13M | -237.68M | -134.28M | -192.88M | -283.38M | -303.24M |
Debt / Equity | 0.01x | - | - | 0.04x | 0.04x | 0.01x | 0.05x | 0.03x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.92x |
Interest Coverage | - | -154.87x | - | - | - | -612.81x | - | - | - | - |
Total Equity | 35.79M▲ 0% | 57.45M▲ 60.5% | 105.09M▲ 82.9% | 131.3M▲ 24.9% | 102.26M▼ 22.1% | 316.2M▲ 209.2% | 247.06M▼ 21.9% | 356.34M▲ 44.2% | 647.93M▲ 81.8% | 661.63M▲ 0% |
Equity Growth % | 15.67% | 60.52% | 82.93% | 24.94% | -22.12% | 209.2% | -21.87% | 44.24% | 81.83% | 159.21% |
Book Value per Share | 2.71 | 2.99 | 4.72 | 5.42 | 3.50 | 8.18 | 5.50 | 6.91 | 10.09 | 8.74 |
Total Shareholders' Equity | 35.79M | 57.45M | 105.09M | 131.3M | 102.26M | 316.2M | 247.06M | 356.34M | 647.93M | 661.63M |
Common Stock | 1.52M | 2.1M | 2.37M | 2.92M | 3.21M | 4.48M | 4.75M | 5.88M | 6.96M | 6.55M |
Retained Earnings | -112.84M | -200.93M | -259.45M | -314.6M | -400.11M | -466.93M | -598.12M | -753.06M | -968.39M | -1.13B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 1.59M | 9.07M | -9.22M | -30.45M | -22.53M | -55.47M | 16.61M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRUS Cash Flow Statement
Merus N.V. (MRUS) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -27.06M | -44.88M | -46.33M | -63.05M | -79.9M | -59.63M | -149.9M | -142.21M | -185.84M | -317.27M |
Operating CF Margin % | -1078.22% | -204.81% | -138.29% | -227.16% | -325.98% | -138.2% | -385.97% | -357.24% | -532.8% | - |
Operating CF Growth % | -7.48% | -65.85% | -3.21% | -36.09% | -26.73% | 25.37% | -151.39% | 5.13% | -30.68% | -1543% |
Net Income | -49.67M | -87.69M | -27.76M | -55.15M | -85.51M | -66.82M | -131.19M | -154.94M | -215.33M | -334.9M |
Depreciation & Amortization | 246.1K | 381.5K | 729.81K | 1.14M | 1.44M | 1.49M | 1.28M | 2.54M | 2.47M | 2.45M |
Stock-Based Compensation | 3.48M | 15.37M | 9.07M | 7.83M | 9.37M | 17.09M | 24.54M | 26.23M | 45.83M | 72.01M |
Deferred Taxes | 20.53M | 31.63M | -7.07M | -89K | -122K | -7K | -1.62M | 842K | -321K | 77K |
Other Non-Cash Items | -34.7K | -1.25M | -1.35M | -1.6M | 9M | -27.25M | -23.93M | 8.88M | -42.81M | 9.55M |
Working Capital Changes | -1.62M | -3.33M | -19.94M | -15.18M | -14.08M | 15.87M | -18.97M | -25.75M | 24.32M | -20.21M |
Change in Receivables | -1.44M | -2.2M | -2.95M | 633K | 1.15M | -4.99M | 1.83M | 1.73M | 1.07M | -17.14M |
Change in Inventory | 181.94K | 6.23M | -743.54K | 2.29M | 4.13M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -127.25K | 605.85K | 706.93K | 22K | -110K | 10.71M | -3.92M | -3.93M | -136K | 13.11M |
Cash from Investing | -429.09K | -49.94M | -22.21M | 24.17M | -1.49M | -146.62M | 2.8M | -27.02M | -220.22M | -93.55M |
Capital Expenditures | -521.64K | -868.58K | -4.21M | -2.6M | -1.29M | -870K | -7.64M | -3.98M | -1.67M | -607K |
CapEx % of Revenue | 20.78% | 3.96% | 12.56% | 9.36% | 5.25% | 2.02% | 19.67% | 10% | 4.78% | 1.19% |
Acquisitions | 0 | 0 | 0 | 375K | 162.9K | 0 | 52K | 52K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 92.55K | 1.11M | 1.46M | -375K | -162.9K | 0 | -52K | -52K | -163K | 657K |
Cash from Financing | 52.8M | 223.41M | 60.86M | 74.23M | 39.52M | 281.95M | 58.74M | 230.09M | 494.01M | 354.22M |
Debt Issued (Net) | -175.63K | -583.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -188.25K | 134.33M | 0 | 48K | 1.45M | 16.85M | 999K | 4.14M | 36.53M | 1.08M |
Net Change in Cash | 25.31M▲ 0% | 111.29M▲ 339.7% | -6.78M▼ 106.1% | 33.08M▲ 587.6% | -34.53M▼ 204.4% | 78.47M▲ 327.2% | -93.31M▼ 218.9% | 56.58M▲ 160.6% | 89.02M▲ 57.3% | -65.54M▲ 0% |
Free Cash Flow | -27.59M▲ 0% | -45.75M▼ 65.9% | -50.53M▼ 10.4% | -65.65M▼ 29.9% | -81.19M▼ 23.7% | -60.5M▲ 25.5% | -157.54M▼ 160.4% | -146.19M▲ 7.2% | -187.5M▼ 28.3% | -317.87M▲ 0% |
FCF Margin % | -1099.01% | -208.78% | -150.84% | -236.52% | -331.23% | -140.22% | -405.64% | -367.24% | -537.58% | -621.16% |
FCF Growth % | -9.06% | -65.86% | -10.45% | -29.91% | -23.68% | 25.49% | -160.41% | 7.2% | -28.26% | -104.03% |
FCF per Share | -2.09 | -2.38 | -2.27 | -2.71 | -2.78 | -1.57 | -3.51 | -2.83 | -2.92 | -4.20 |
FCF Conversion (FCF/Net Income) | 0.57x | 0.69x | 1.87x | 1.28x | 1.14x | 1.02x | 1.22x | 1.01x | 0.89x | 0.95x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 320K | 322K | 635K | 0 | 3.1M | 2.8M | 0 |
MRUS Key Ratios
Merus N.V. (MRUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -142.17% | -138.94% | -30.41% | -41.6% | -59.94% | -28.06% | -43.5% | -46.52% | -41.39% | -50.62% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -547.69% | -117.19% | -77% | -74.61% | -64.54% |
Gross Margin | -634.02% | -55.72% | -42.7% | -78.85% | -133.91% | -99.94% | 74.37% | 73.62% | 37.15% | -217.5% |
Net Margin | -1889.92% | -295.57% | -73.77% | -177.15% | -285.59% | -136.06% | -315.48% | -352.56% | -595.93% | -654.43% |
Debt / Equity | 0.01x | - | - | 0.04x | 0.04x | 0.01x | 0.05x | 0.03x | 0.02x | 0.02x |
Interest Coverage | - | -154.87x | - | - | - | -612.81x | - | - | - | - |
FCF Conversion | 0.57x | 0.69x | 1.87x | 1.28x | 1.14x | 1.02x | 1.22x | 1.01x | 0.89x | 0.95x |
Revenue Growth | 31.76% | 773.11% | 52.86% | -17.15% | -11.69% | 76.02% | -9.99% | 2.5% | -12.38% | 55.9% |
Related:MRUS Dividend History·MRUS Revenue History·MRUS Price History·MRUS P/E History·MRUS Financial Ratios·MRUS Institutional Holders
MRUS SEC Filings & Documents
Merus N.V. (MRUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRUS Frequently Asked Questions
Merus N.V. (MRUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Merus N.V. (MRUS) reported $51.2M in revenue for fiscal year 2024. This represents a 9071% increase from $0.6M in 2013.
Merus N.V. (MRUS) saw revenue decline by 12.4% over the past year.
Merus N.V. (MRUS) reported a net loss of $334.9M for fiscal year 2024.
Dividend & Returns
Merus N.V. (MRUS) has a return on equity (ROE) of -41.4%. Negative ROE indicates the company is unprofitable.
Merus N.V. (MRUS) had negative free cash flow of $317.9M in fiscal year 2024, likely due to heavy capital investments.